<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103333</url>
  </required_header>
  <id_info>
    <org_study_id>992AN001</org_study_id>
    <nct_id>NCT04103333</nct_id>
  </id_info>
  <brief_title>Angelman Syndrome (AS) Biomarker Study</brief_title>
  <official_title>A Study to Explore Cerebrospinal Fluid and Blood Biomarkers in Participants With Angelman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to measure ubiquitin-protein ligase E3A (UBE3A)&#xD;
      protein levels in cerebrospinal fluid (CSF) and to evaluate its utility as a biomarker in&#xD;
      support of the development of therapies for AS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ubiquitin-Protein Ligase E3A (UBE3A) Protein Levels in Each Age Group</measure>
    <time_frame>Baseline up to Day 33</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>UBE3A Protein Levels in Each Genotype Group</measure>
    <time_frame>Baseline up to Day 33</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Angelman Syndrome</condition>
  <condition>Chromosome 15q Duplication (dup15q) Syndrome</condition>
  <arm_group>
    <arm_group_label>Angelman Syndrome: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 0-6 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angelman Syndrome: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 7-12 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angelman Syndrome: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 13-18 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angelman Syndrome: Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 19-50 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dup15q Syndrome: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 0-6 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dup15q Syndrome: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 7-12 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dup15q Syndrome: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 13-18 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dup15q Syndrome: Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 19-50 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar Puncture</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Angelman Syndrome: Group 1</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 2</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 3</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 4</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 1</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 2</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 3</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Collection</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Angelman Syndrome: Group 1</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 2</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 3</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 4</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 1</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 2</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 3</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Ability of the participant's legally authorized representative (LAR) to understand the&#xD;
             purpose and risks of the study and provide signed and dated informed consent and&#xD;
             authorization to use confidential health information in accordance with national and&#xD;
             local privacy regulations&#xD;
&#xD;
          -  Must have genetically confirmed diagnosis of AS (UBE3A deletion, UBE3A mutation,&#xD;
             paternal uniparental disomy, or imprinting center defect) or dup15q syndrome (with&#xD;
             number and size of duplications of 15q specified) provided by the Investigator&#xD;
&#xD;
          -  Must be scheduled for a procedure unrelated to the study that will involve&#xD;
             administration of general anesthesia or conscious sedation.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Lumbar Puncture (LP) procedure less than 30 days before the Sampling Visit&#xD;
&#xD;
          -  Any contraindications to having an LP&#xD;
&#xD;
          -  The blood and CSF collection will, in the opinion of the Investigator, inhibit, in&#xD;
             some way, the prescheduled procedure that requires anesthesia or sedation&#xD;
&#xD;
          -  Current enrollment or past enrollment in an interventional clinical study in which an&#xD;
             investigational gene therapy or antisense oligonucleotide (ASO) is/was administered&#xD;
&#xD;
          -  Enrollment in an interventional clinical study in which an investigational small&#xD;
             molecule/antibody treatment or approved small molecule/antibody therapy is&#xD;
             administered within 1 month (or 5 half-lives of study agent, whichever is longer)&#xD;
             prior to the Sampling Visit which, under the judgement of the Investigator and/or&#xD;
             Sponsor would affect UBE3A and other CSF biomarker levels. Use of approved or&#xD;
             investigational small molecule therapies which would not impact the biomarkers above&#xD;
             will be eligible with Sponsor approval prior to enrollment (e.g., anti-epileptic drugs&#xD;
             being studied in alternative formulation, other derivatives of benzodiazepines, or&#xD;
             other same class drugs as those already permitted as part of the study).&#xD;
&#xD;
        Note: Other protocol defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rady Childrens Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Guevara</last_name>
      <phone>858-966-1700</phone>
      <phone_ext>221543</phone_ext>
      <email>aguevara1@rchsd.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush Medical College</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Do</last_name>
      <phone>312-942-7250</phone>
      <email>kim_do@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital</name>
      <address>
        <city>Carolina</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Riehl</last_name>
      <phone>919-962-8462</phone>
      <email>Hannah.riehl@cidd.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-343-8010</phone>
      <email>vcc@vumc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angelman Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

